Summary
Bristol-Myers Squibb Company (BMY) reported its financial results for the quarter and six months ended June 30, 2015. The company experienced a net loss of $130 million for the quarter, a significant decrease from the prior year's net earnings of $333 million, largely driven by increased research and development expenses. For the six-month period, net earnings attributable to BMS were $1.06 billion, down from $1.27 billion in the same period last year. Total revenues showed growth, up 7% for both the quarter and the six-month period, primarily fueled by strong performance in key products like Eliquis, Opdivo, and the Hepatitis C Franchise, partially offset by the impact of foreign currency fluctuations and the expiration of Abilify U.S. commercialization rights. The company's R&D spending saw a substantial increase due to the acquisition of Flexus Biosciences for $800 million upfront, aimed at bolstering its immuno-oncology pipeline. Management highlighted the strategic importance of Opdivo, which received significant regulatory approvals in Europe and strong results from Phase III trials, positioning it as a key growth driver. Despite the quarterly loss, the company maintained a strong liquidity position, with cash, cash equivalents, and marketable securities totaling over $10 billion. The company anticipates lower earnings in the remaining quarters of 2015 due to ongoing product transitions and increased investment in new launches.
Financial Highlights
57 data points| Revenue | $4.16B |
| Cost of Revenue | $1.01B |
| Gross Profit | $3.15B |
| R&D Expenses | $1.86B |
| SG&A Expenses | $1.14B |
| Operating Expenses | $4.11B |
| Interest Expense | $49.00M |
| Net Income | -$130.00M |
| EPS (Basic) | $-0.08 |
| EPS (Diluted) | $-0.08 |
| Shares Outstanding (Basic) | 1.67B |
| Shares Outstanding (Diluted) | 1.67B |
Key Highlights
- 1Net loss of $130 million for the three months ended June 30, 2015, compared to net earnings of $333 million in the prior year's quarter.
- 2Total revenues increased by 7% to $4.16 billion for the quarter and 7% to $8.20 billion for the six months, driven by strong sales of Eliquis, Opdivo, and Hepatitis C Franchise products.
- 3Research and Development expenses increased significantly, notably due to an $800 million upfront payment for the acquisition of Flexus Biosciences, aimed at strengthening the oncology pipeline.
- 4Opdivo (nivolumab) received important regulatory approvals in the EU for melanoma and demonstrated positive results in Phase III trials for both melanoma and non-small cell lung cancer (NSCLC).
- 5The company's liquidity remains strong, with $10.1 billion in cash, cash equivalents, and marketable securities as of June 30, 2015.
- 6Abilify U.S. commercialization rights expired on April 20, 2015, leading to a significant decrease in related revenues.
- 7The company is actively managing its capital structure, including debt redemptions and issuances, and expects capital expenditures to increase significantly for manufacturing capabilities.